Kerendia finerenone fda approval date?

Kerendia (finerenone) was approved by the U.S. FDA on July 16, 2021. It’s indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular events, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. If you’d like, I can share the FDA press release or labeling details.